

## **JW Therapeutics accelerates R&D of T cell-based immunotherapies in China**

27 October 2022 | News

### **Initial focus on accelerating development of 2seventy's MAGE-A4 programme in solid tumours in China**



JW Therapeutics and 2seventy bio have announced a strategic alliance to establish a translational and clinical cell therapy development platform designed to more rapidly explore T cell-based immunotherapy products in the Chinese mainland, Hong Kong (China), and Macao (China).

The initial focus of the collaboration is US-based startup 2seventy's MAGE-A4 TCR programme in solid tumours which is being developed as part of collaboration with Regeneron. MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumour types. The programme is designed to develop T cell receptor (TCR) therapies for the treatment of MAGE-A4 positive solid tumours.

Under the terms of the agreement, 2seventy will grant Chinese startup JW Therapeutics a license for the MAGE-A4 cell therapy in the Chinese mainland, Hong Kong (China), and Macao (China). JW Therapeutics will be responsible for development, manufacturing, and commercialisation within China. 2seventy is eligible to receive milestones and royalties on product revenues in China. Additionally, 2seventy may leverage the early clinical data generated under the collaboration to support development in other geographies.